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Introduction: Progression of arterial involvement is often observed in patients with Takayasu arteritis (TA) thought
to be in remission. This reflects the failure of currently used biomarkers and activity criteria to detect smouldering
inflammation occurring within arterial wall. Pentraxin-3 (PTX3) is a soluble pattern recognition receptor produced at
sites of inflammation and could reveal systemic as well as localized inflammatory processes. We verified whether
the blood concentrations of PTX3 and of C-reactive protein (CRP) in patients with Takayasu arteritis (TA) might
reflect vascular wall involvement, as assessed by signal enhancement after contrast media administration, and the
progression of arterial involvement.
Methods: A cross-sectional single-centre study was carried out on 42 patients with TA that comprised assessment
of PTX3, of CRP and erythrocyte sedimentation velocity (ESR). In total, 20 healthy controls and 20 patients with
Systemic Lupus Erythematous (SLE) served as controls. Vascular imaging was carried out by magnetic resonance
angiography, doppler ultrasonography and computed tomography angiography.
Results: Patients with TA and SLE had higher plasmatic PTX3 and CRP concentrations than healthy controls
(P = 0.009 and 0.017, respectively). PTX3 levels did not correlate with those of CRP. Patients with active systemic TA
had significantly higher concentrations of CRP but similar levels of PTX3 than patients with quiescent disease. In
contrast, patients with vascular inflammation detectable at imaging had higher PTX3 concentrations (P = 0.016)
than those in which vessel inflammation was not evident, while CRP levels were similar. The concentration of PTX3
but not that of CRP was significantly higher in TA patients with worsening arterial lesions that were not receiving
antagonists of tumor necrosis factor-α or interleukin-6.
Conclusions: Arterial inflammation and progression of vascular involvement influence plasma PTX3 levels in TA, while
levels of CRP accurately reflect the burden of systemic inflammation. These results support the contention that PTX3
reflects different aspects of inflammation than CRP and might represent a biomarker of actual arteritis in TA.* Correspondence: tombetti.enrico@hsr.it
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Figure 1 Study flow diagram.
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Takayasu arteritis (TA) is a rare, idiopathic, chronic-
relapsing inflammatory disease, typically affecting young
women, characterized by considerable morbidity and
mortality [1-4]. Inflammation primarily localizes in the
large arteries, such as the aorta, the pulmonary artery
and their major branches. Arterial inflammation results
in thickening of the vessel wall with eventual stenosis/
occlusion, or in vessel dilatation and aneurysm forma-
tion [1,4,5]. The lack of accepted and reliable criteria for
disease activity has limited clinical management of pa-
tients as well as clinical research. Moreover, commonly
used biomarkers do not accurately discriminate active
and inactive disease [1,6]. Erythrocyte sedimentation rate
(ESR) and C-reactive protein (CRP) levels, which are ele-
vated during active phases of the disease in almost half
of the cases, are unreliable markers of disease activity,
vascular inflammation and progression [4,5,7]. Multi-
item activity criteria have been proposed, such as the
National Institutes of Health (NIH) criteria [5]. However
they lack accuracy and patients considered inactive often
undergo vascular progression [5,7], suggesting that these
criteria do not take into account smouldering inflammation
occurring within vessel walls. Conversely, not all TA pa-
tients experiencing systemic inflammatory flares undergo
anatomical progression of the vascular involvement [8].
Aortic regurgitation, hypertension, retinopathy and an-
eurysms, all contribute to the mortality of patients with
TA [9]. They depend on the characteristics of the in-
flammatory involvement and of the remodelling of arter-
ies [10,11]. Therefore to prevent vascular progression is
a reasonable hard outcome and a therapeutic goal in TA.
The availability of reliable imaging tools and of bio-
markers for the assessment of vascular involvement is
thus essential for the management of patients with TA.
Pentraxin-3 (PTX3) is a long pentraxin produced at
sites of inflammation in response to microbial or sterile
stimuli [12,13]. PTX3 has a non-redundant role in the
protective response against selected pathogens and re-
gulates various events implicated in TA pathogenesis,
including innate immunity and inflammation, extracel-
lular matrix deposition, tissue remodelling and vascular
homeostasis [12-14]. PTX3 has been proposed to reflect
disease activity in small vessel vasculitis [15,16] and
more recently in giant cell arteritis [17] and TA [18-20].
Here we explore the link between PTX3 plasma levels,
vascular inflammation and vascular progression.
Methods
Study sample
Consecutive patients with TA (n = 51) have been evaluated
in 2013 at San Raffaele Scientific Institute in Milan. All pa-
tients fulfilled the American College of Rheumatology
(ACR) criteria for TA [21] and had been extensivelyevaluated to exclude conditions that could mimic the dis-
ease such as Behçet disease, Cogan syndrome, Kawasaki
disease, giant cell arteritis, Marfan syndrome, Ehler-Danlos
syndrome, neurofibromatosis and infective aortitis. We
performed a cross-sectional analysis between April and
August 2013, excluding nine patients who did not attend
a visit in this period. The final sample comprised 42 pa-
tients (Figure 1): 20 healthy blood donors and 20 consecu-
tive patients fulfilling the ACR criteria for systemic lupus
erythematous (SLE) who visited at our outpatient clinic in
May 2013 served as controls. Subjects in control groups
and patients with TA had similar age and sex distribution.
All subjects gave written informed consent for parti-
cipation in the study and the Institutional Review Board
(Comitato Etico dell’Ospedale San Raffaele, Milano) ap-
proved storage of the plasma in the biobank.
Biomarkers
Plasma concentrations of PTX3 were measured by a sand-
wich enzyme-linked immunosorbent assay, as previously
described [22]. This assay is highly sensitive and specific
[22,23]. No cross-reactions were observed with other pen-
traxins, including CRP and serum amyloid P. CRP was
measured with a latex-enhanced immunoturbidimetric
assay (ADVIA Chemistry System, Bayer Healthcare AG,
Leverkusen, Germany). ESR was evaluated by the Wes-
tergren method. There were no samples missing for PTX3
and CRP assessment but three samples were missing for
ESR. Samples were analysed in a random order and in a
blinded manner. Systemic activity of TA was evaluated
according to NIH criteria [5]. Complement levels and
anti-DNA antibody titres of patients with SLE were also
assessed and disease activity assessed using the validated
index systemic lupus erythematosus disease activity index
(SLEDAI).
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All patients with TA were initially evaluated by magnetic
resonance angiography (MRA) and vascular ultraso-
nography (US). Two patients had contraindications to
MRA and computed tomography angiography (CTA)
was used instead. MRA was performed with a 1.5-T
magnetic resonance whole body scanner (Achieva Nova
Master; Philips Medical System, Best, The Netherlands)
with phased-array head and neck or phased-array thor-
acic dedicated coils. Morphologic sequences (PD Black
Blood TSE: field of view (FOV) 260 × 152; acquisition
(Acq) matrix = 260 × 264; reconstruction (Recon) matrix =
528; echo time/repetition time (TE/TR) = 20/2 beats;
ECG triggered; in expiratory breath-hold of approxi-
mately 10 sec) were performed to evaluate vessel wall
thickening. First pass MRA dynamic sequences targeted
on the thoraco-abdominal aorta and supra-aortic trunks
(FOV 450 × 390; Acq matrix = 352 × 200; Recon matrix =
670; Acq voxel = 1.28/1.90/3.00; Recon voxel = 0.67/
0.67/1.5; slice thickness = 1.5 mm; TR/TE/α = 4.6/1.35/
40; Acq time = 21 sec) were performed during contrast
media infusion (Gadovist®: 1 nmol/ml Bayer-Shering
Pharma, Berlin, Germany). High resolution (HR) se-
quences were performed before and after contrast ad-
ministration (Coronal HR 3D FFE: FOV 360 × 276; Acq
matrix = 684 × 521; Recon matrix = 880; slice thickness =
0.8 mm; TR/TE/FA = 6.3/2.1/20; Acq time = 3 minutes
and 28 seconds). These sequences allow the evaluation of
vessel wall thickness up to 1 mm. We were actively look-
ing for approaches to evaluate vessel wall enhancement
because Gadofosveset Trisodium was retired [24]: the
evaluation of vessel wall enhancement was given to radi-
ologist interpretation. CTA was performed with a Bril-
liance CT 64-channel scanner (Philips Medical System®).
The evaluation of vessel wall enhancement was given to
radiologist interpretation because no cutoff value has
been established with this technique. CT was performed
with 130 ml of Ultravist 370 (Bayer-Shering Pharma,
Berlin, Germany) administration at a rate of 5 ml/sec. US
was performed with the iU22 Matrix Ultrasound system
(Philips Medical System®). US and CTA evaluations
assessed the carotid, subclavian, abdominal and femoral
regions, while MRA focused on thoraco-abdominal or
cervico-thoracic regions according to disease involve-
ment. Two radiologists, blinded to the clinical status of
patients, performed MRA, CTA and US examinations.
Each lesion was evaluated independently. Variables evalu-
ated for each lesion at MRA and CTA included width,
length, residual lumen and contrast enhancement. On
US, lesion width, residual lumen, blood-flow peak systolic
rate and the presence of the halo sign were assessed. Im-
aging examinations are repeated yearly or in the case of
relapses, until disease enters the tardive phase, with clin-
ical and morphological stability for at least 3 to 5 years.To evaluate vascular progression we relied on clinical
records of US examinations and on review of imaging
data for MRA and CTA. Progression was defined as
appearance of novel lesions or as increase in width and/
or length and/or percentage of luminal stenosis when
established lesions were evaluated. Imaging evaluation of
vascular progression was carried out yearly or when
there was disease relapse. Atherosclerotic lesions were
identified based on suggestive localization at arterial
branches, eccentric appearance of the lesions, short and
focal lesions, inhomogeneous content and irregular lu-
minal border on US, the presence of parietal calcifications
on the luminal side of the lesion and absence of halo signs
or adventitial thickening on US.
Statistical analysis
We express plasma PTX3 and CRP levels, ESR and other
scalar variables as medians values and ranges. Mean
values are also shown. The Mann-Whitney U-test was
used to compare biomarkers between patients with TA
and controls or between various subgroups of patients
with TA stratified according to the presence or the ab-
sence of wall enhancement, of vascular progression, of
active disease and history of aneurysms. The Kruskal-
Wallis test was used to compare values of biomarkers in
the various classes of arterial involvement [25]. We used
the Spearman rank correlation coefficient to describe
the correlation between PTX3 and CRP and between
PTX3 and ESR. A two-tailed P-value less than 0.05 was
considered to represent a statistically significant dif-
ference. All statistical analysis was performed with IBR®
SPSS® statistics, version 20 (IBM corporation, Armonk,
NY, USA).
Results
Patient characteristics
Table 1 summarizes the demographic and clinical cha-
racteristics, ESR, CRP and PTX3 levels of the 42 patients
(39 women and 3 men) with TA. Median age at the study
entry was 46 years (range 23 to 66 years) and median age
at disease onset was 30 years (range 17 to 56 years).
Demographic features were similar in the control groups
(20 healthy women with a median age of 37 years (range
24 to 57 years), 18 women and 2 men with SLE and a
median age of 44 years (range 21 to 61 years)). Most TA
patients had widespread diffuse arterial involvement
(angiographic class II or V). Sixteen patients (38%) had ar-
terial aneurysms and 38 patients (90%) were on treatment:
30 patients received steroids, 30 immunosuppressive
agents (12 azathioprine, 11 methotrexate, 4 mofetil myco-
phenolate, 2 sirolimus, 1 cyclophosphamide), 16 TNF-
blockers, 2 tocilizumab and 1 rituximab. Twelve patients
(29%) fulfilled the NIH criteria for active TA. Arterial wall
enhancement was detectable in 16% (5/30, of whom 3 had
Table 1 Characteristics of the patients with Takayasu
arteritis (n = 42)
Variables Value
Qualitative variables, number (percent)
Sex, female:male 39:3
Class of vascular involvement
1 4 (10%)
2A 4 (10%)
2B 3 (7%)
3 1 (2%)
4 0
5 30 (71%)
Coronary involvement 6 (14%)
Pulmonary artery involvement 13 (31%)
Aneurysms 16 (38%)
Steroids 30 (71%)
Immunosuppressive therapy 30 (71%)
Azathioprine 12 (29%)
Methotrexate 11 (26%)
Mycophenolate 4 (10%)
Sirolimus 2 (5%)
Cyclophosphamide 1 (2%)
Biologic therapy 19 (45%)
TNF-blockers 16 (38%)
Tocilizumab 2 (5%)
Rituximab 1 (2%)
Active disease (National Institutes of Health criteria) 12 (29%)
Vascular enhancement (n = 30) 5 (16%)
Vascular progression (n = 40) 9 (22%)
Scalar variables, mean, median (range)
Age, years 45, 46 (23 to 66)
Age at disease onset, years 33, 30 (17 to 56)
Disease duration, years 12, 10 (0 to 34)
Prednisone (PDN) dose, mg/day (n = 30) 9.2, 5 (3 to 35)
Erythrocyte sedimentation rate, mm/h 22, 15 (1 to 78)
Serum C-reactive protein, mg/l 6.2, 2.3 (0.1 to 40)
Serum Pentraxin-3, ng/ml 8.4, 5.5 (1.3 to 55)
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the patients for which recent previous imaging data were
available (Table 1).
Elevated plasma PTX3 concentrations reflect ongoing
vascular inflammation in TA patients
The PTX3 concentrations in the blood of patients with TA
(median 5.5 ng/ml, range 1.3 to 55 ng/ml) and SLE (me-
dian 5.1 ng/ml, range 0.7 to 9.2 ng/ml) were significantlyhigher than those in healthy controls (median 3.9 ng/ml,
range 1.4 to 6.5 ng/ml, P = 0.009 and 0.017 respectively).
The PTX3 concentrations were similar in patients with TA
and SLE (Figure 2A). Classes of arterial involvement or
aneurysmal TA did not influence PTX3 and CRP concen-
trations or ESR (Table 2). PTX3 levels in TA patients did
not correlate with CRP levels or with ESR (Figure 2B and
C). PTX3 levels were similar in patients identified accord-
ing to the NIH criteria as having active or inactive TA. In
contrast, CRP levels and ESR were higher in patients
deemed to have active TA according to the NIH criteria
(respectively P = 0.013 and P = 0.011, Figure 2D-F). The
results suggest that events other than systemic inflamma-
tion, which is well identified by NIH criteria and for which
CRP and ESR are effective biomarkers, are responsible for
PTX3 elevation in patients with TA.
The scenario changes when patients are stratified based
on the presence of vascular inflammation, assessed by the
presence of vascular wall enhancement after contrast
media infusion (Figure 2G-I). Concentrations of PTX3
were higher in patients with wall enhancement (median
16 ng/ml (range 6.2 to 55 ng/ml) versus 5.2 ng/ml (range
2.5 to 44 ng/ml), P = 0.016). CRP concentrations and ESR
were similar in the two groups. Neither marker dis-
criminated patients with or without evidence of progres-
sion of arterial lesions at longitudinal imaging follow-up
(Figure 3A-C).
Anti-cytokine therapy influences the ability of PTX3 to
identify vascular inflammation and progression in TA
Eighteen of the forty-two patients (43%) were treated
with TNF-α or IL-6-receptor inhibitors. Inflammatory
cytokines are known inducers of PTX3 expression and
release. Indeed, the median PTX3 concentration of TA
patients with arterial wall enhancement who were not
receiving TNF-α or IL-6-receptor inhibitors (n = 24) was
12 ng/ml (range 9.2 to 15 ng/ml) versus 5.2 ng/ml (range
3.0 to 9.3 ng/ml) in those without wall enhancement
(P = 0.044, Figure 4A). In contrast CRP levels or ESR
were similar regardless of imaging evidence of vessel
wall inflammation (Figure 4B, C). In the absence of anti-
cytokine therapies, PTX3 concentrations were higher in
TA patients with vascular progression than in stable pa-
tients (median 8.4 ng/ml (range 2.2 to 16 ng/ml) versus
4.4 ng/ml (range 1.3 to 7.1 ng/ml), P = 0.010, Figure 4D).
CRP levels were similar in patients with and without
vascular progression (Figure 4E) while ESR was higher
in patients undergoing progression (median 31 mm/h
(range 8 to 73 mm/h) versus 11 mm/h (range 1 to
78 mm/h), P = 0.036, Figure 4F).
Discussion
Here we show that plasmatic PTX3 in patients with TA
reflect specific features of vessel involvement of TA,
Figure 2 (See legend on next page.)
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Figure 2 Pentraxin-3 (PTX3) levels reflect ongoing vascular inflammation in Takayasu arteritis (TA). (A) Plasma concentrations of PTX3 in
patients with TA and matched systemic lupus erythematosus (SLE) patients or healthy controls. (B, C) Plasma concentrations of PTX3 in patients
with TA do not correlate in patients with C-reactive protein (CRP) or erythrocyte sedimentation rate (ESR) levels. (D-F) CRP and ESR levels, but not
PTX3, identify ongoing systemic inflammation in patients with TA, as assessed using the National Institutes of Health (NIH) criteria for active and
inactive disease. (G-I) PTX3, CRP and ESR levels stratified on the basis of vascular wall enhancement. PTX3 is a more sensitive maker of vascular
inflammation, based on the presence of vascular wall enhancement after contrast medium infusion, than CRP of ESR. (J) Representative images of
magnetic resonance angiography (MRA) assessment of vascular inflammation in a patient with TA, with vivid enhancement in the thickened
arterial wall of the anonym and subclavian arteries (white arrows); patent lumen of the anonym artery (black arrowhead); sub-occluded lumen of
the subclavian artery (white arrowhead). (K) MRA image of a patient with TA with thickened left carotid artery with enhancement (black arrows)
and thickened right carotid artery without enhancement (white arrows); white arrowheads indicate patent arterial lumen.
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the specific feature of PTX3, which is locally produced
at sites of inflammation and plays an emerging role in
vessel biology, and whose generation is possibly elicited
in response to stimuli distinct from those that trigger
the production of other pentraxins, such as CRP
[12,13,15,16,18-20,26-28]. PTX3 is involved in the main-
tenance of vascular homeostasis: it plays a protective
role in various vessel diseases in which inflammation
and vascular remodelling both contribute to the clinical
outcome, such as atherosclerosis [29] or the response to
balloon angioplasty [30]. PTX3 is a novel and informative
marker of cardiovascular risk and of atherosclerotic
plaque inflammation, which possibly reflects diverse facets
of the inflammatory response from commonly used acute
phase reactants [31-33].
Our results confirm that CRP and ESR reveal the sys-
temic inflammatory burden associated with TA. However,
these markers apparently fail to provide information on
the events that take place specifically within the inflamed
vessel walls: their variations do not correlate with the
presence of vascular inflammation as assessed by the pres-
ence of contrast enhancement and the progression of the
vascular wall involvement. In the subgroup of patients not
treated with anti-cytokine therapy, ESR was higher in pa-
tient swith vascular progression. This correlation was notTable 2 ESR, and levels of CRP and PTX3 in TA patients
Erythrocyte sedimentation rate,
Class of vascular involvement
1 (n = 4) 28, 34 (4 to 44)
2A (n = 4) 15, 17 (7 to 22)
2B (n = 3) 33, 33 (29 to 38)
3 (n = 1) 4.0
4 (n = 0) NA
5 (n = 30) 21, 15 (1 to 78)
Presence of aneurysms (n = 16) 23, 15 (1 to 78)
Absence of aneurysms (n = 26) 20, 16 (2 to 68)
Active (NIH criteria n = 12) 34, 38 (3 to 73)
Inactive (NIH criteria n = 30) 16, 12 (1 to 78)
Results are presented as mean, median (range). NA, not applicable; NIH, National Inevident in patients treated with biologic agents. Recent
data indicate that vascular inflammation and progression
occur even after ESR and CRP levels have abated upon
the pharmacological blockade of inflammatory cytokines
[1,34,35] suggesting that vascular inflammation in TA de-
pends on multiple pathways, some of which remain
strictly localized within the vascular lesions and do not
result in an acute-phase response [10,11]. Moreover, the
relationship between vascular progression and inflamma-
tion is still elusive, as various non-overlapping inflamma-
tory pathways sustain vascular remodelling [10,11,36-39].
Recent studies have shown that PTX3 blood levels are
increased in TA and suggest that it might be generated
within the inflamed vessel wall, possibly by vasa vasorum
endothelial cells or macrophages within the inflammatory
infiltrate [18-20]. These studies observed a correlation bet-
ween plasma PTX3 concentration and activity in TA. Our
results are consistent with significant correlation between
variations of systemic PTX3 levels and the presence of en-
hancement within arterial lesions on imaging assessment.
PTX3 identified vascular progression only in patients who
were not being treated with anti-cytokine agents. This
is in agreement with the observation that several in-
flammatory cytokines, and TNF-α in particular, foster
PTX3 expression and release [12,40]. IL-6 is not known to
directly induce PTX3 expression and release [27,40].mm/h C-reactive protein, mg/l Pentraxin-3, ng/ml
8.3, 6.0 (2.7 to 19) 5.5, 6.2 (2.9 to 6.7)
3.0, 1.0 (0.1 to 11) 15, 6.8 (6.2 to 44)
17, 12 (1.2 to 37) 5.3, 5.0 (3.9 to 7.0)
2.0 6.3
NA NA
5.5, 1.9 (0.1 to 40) 8.2, 5.1 (3.0 to 5.1)
5.7, 2.7 (0.3 to 40) 6.6, 5.8 (1.3 to 23)
6.9, 1.2 (0.1 to 37) 11, 5.0 (2.2 to 55)
12, 8.6 (0.3 to 40) 12, 6.9 (2.2 to 55)
3.5, 1.9 (0.1 to 19) 7.1, 5.0 (1.3 to 44)
stitutes of Health.
Figure 3 Pentraxin-3 (PTX3) levels and progressive vascular involvement in Takayasu arteritis (TA). (A-C) PTX3 and C-reactive protein
(CRP) concentration and erythrocyte sedimentation rate (ESR) levels in patients with TA stratified according to the presence of progression of
vascular wall involvement on longitudinal imaging follow up. (D, E) Representative images show progression of vascular wall involvement
between May 2012 (D) and May 2013 (E). Wall thickness in the right carotid artery changed from 1.7 mm in May 2012 to 2.7 mm in May 2013
(white arrows); arterial lumen was patent and stenotic in May 2012, and was occluded in May 2013 (white arrowheads).
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IL-1β, thus, indirectly modulating PTX3 levels.
NIH criteria have a high sensitivity to systemic inflam-
mation in TA [5], and we did not observe correlation bet-
ween plasma PTX3 and TA activity evaluated with these
criteria. Previous studies that evaluated plasma PTX3 con-
centration in TA defined disease activity with other, ad
hoc-created criteria that more accurately reflect arterial in-
volvement [18-20]. One of these studies was performed at
our institution before the widespread use of biologic
agents [18]. It is possible that the correlation between
plasma PTX3 and TA activity observed in previous re-
ports could be due to a smaller fraction of patients re-
ceiving anti-cytokine therapy and by using definitions
of disease activity that are less influenced by systemicinflammation than NIH criteria [18]. These results rein-
force the hypothesis that the progression of arterial in-
volvement in TA depends on a variety of mechanisms,
including remodelling as well as inflammation of the
arterial wall, which sometimes causes the acute-phase
response and systemic inflammatory symptoms.
Our study has limitations: first it was an observational
cross-sectional study. Second, TA is a rare disease and
large cohorts are difficult to establish. The relatively small
number of patients might have limited the statistical
power of the study. Finally, we did not use histology as a
reference for assessing vascular inflammation. However,
surgery is quite rarely performed in TA, and to obtain
arterial specimens to confirm the results of imaging is dif-
ficult. MRI can reveal oedema or contrast enhancement
Figure 4 Anti-cytokine treatment interferes with the performance of Pentraxin-3 (PTX3) as a biomarker in Takayasu arteritis (TA). (A-C)
Plasma PTX3, C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR) levels in patients with TA without anti-cytokine therapy, stratified
according to the presence of vascular wall enhancement after contrast medium infusion. (D-F) Concentrations of PTX3, CRP and ESR in patients
with TA without anti-cytokine therapy, stratified according to the progression of vascular wall involvement on longitudinal imaging follow up.
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ated with ongoing inflammation. Contrasting results are
reported in the MRI assessment of TA activity as assessed
by NIH criteria [24,41]. However, NIH criteria could not
accurately reflect arterial inflammation and progression
[5,7]. Thus, although there is no consensus on the pre-
ferred mode and the protocol for the assessment of arte-
rial inflammation [42], imaging currently remains the only
practical way to study local vessel inflammation in TA.
Conclusions
Unlike CRP and ESR, plasma PTX3 appears to be
scarcely influenced by overt and systemic inflammation
in TA. In contrast, PTX3 levels are increased in the
presence of vascular wall enhancement, which could re-
flect ongoing arterial inflammation. In the absence of
anti-cytokine therapy, plasma PTX3 is also significantly
higher in patients experiencing longitudinal disease pro-
gression. PTX3 may thus be used as a biomarker of ac-
tual arteritis in TA.Abbreviations
CRP: C-reactive protein; CTA: computer tomography angiography;
ESR: erythrocyte sedimentation rate; FFD: Fast Field Echo; HR: High Resolution;
IL: interleukin; MRA: magnetic resonance angiography; NIH: National Institutes of
Health; PD: Proton Density; PTX3: Pentraxin-3; SLE: systemic lupus erythematous;
TA: Takayasu arteritis; TE: Time Echo; TNF: tumour necrosis factor; TR: Time
Repetition; TSE: Turbo spin Echo; US: ultrasonography.
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